$ICCC

IMMUCELL CORP /DE/ (ICCC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ImmuCell ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results For Immediate Release PORTLAND, Maine – October 12, 2026 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal

ImmuCell (ICCC) reported preliminary Q3 2026 sales growth of 51%, 36%, and 37% for three product lines. The company attributes this to sales team expansion and improved manufacturing. ImmuCell will discontinue early sales reporting, aligning with SEC practices, and will discuss full financial results on a conference call on November 13, 2026.

ImmuCell (ICCC) reported Q2 2026 earnings with product sales of $7.2M, up 11.5% YoY, and net income per diluted share of $0.20. Gross margin decreased to 33.9% from 43.7% YoY due to manufacturing costs. The company is investing in capacity expansion and focusing on its First Defense product line, with U.S. sales growing 27.7% YoY and market share increasing to 19%. Cash and cash equivalents were $8.9M as of June 30, 2026.

ImmuCell (NASDAQ:ICCC) reported Q2 gross margin of 33.9% of product sales, down from 43.7% a year earlier and 11.1 points below Q1 2026, citing lower output, about $150,000 in scrap, and Re-Tain cost shifts. U.S. sales rose 32.5% in H1 2026; distributor volumes grew 24% YoY. The company plans $3.5M freeze-drying and $4.5M liquids capacity expansions through 2027.

IMMUCELL CORP /DE/ (ICCC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026 For Immediate Release PORTLAND, Maine – August 13, 2026 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops,

Biotech stocks hit 52-week highs on July 10, 2026. American Well (AMWL) reached $10.16, citing Nature coverage of SilverCloud and insurer-related deals, and guided 2026 revenue to $195M-$205M. Cue Biopharma (CUE) hit $45.50 amid a ~$50M private placement. ImmuCell (ICCC) rose to $11.59 after Q2 sales of $7.2M. Scholar Rock (SRRK) hit $58.49 on BLA acceptance for apitegromab, with FDA response due by Sept. 30. Faeth (FTH) touched $36.89 on PIKTOR trial timelines.

ImmuCell (Nasdaq: ICCC) reported preliminary, unaudited sales for Q2 2026. Total product sales were $7.2 million, up 11.5% year over year, with domestic sales up 27.7% and international down 38.9%. For the first six months, sales rose 20.9% to $17.5 million. Management will discuss results on Aug. 14, 2026.

IMMUCELL CORP /DE/ (ICCC) filed an SEC Form 8-K — Results of Operations and Financial Condition. iccc20260708_8k.htm false 0000811641 0000811641 2026-07-09 2026-07-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event repo

te Boekhorst Paul Francis Olivier (President and CEO) purchased 8,000 shares of IMMUCELL CORP /DE/ (ICCC) at $9.50 on 2026-06-18.

IMMUCELL CORP /DE/ (ICCC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. iccc20260615_8k.htm false 0000811641 0000811641 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event repo